This page shows the latest filgotinib news and features for those working in and with pharma, biotech and healthcare.
This includes Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib).
NHS Scotland will now be able to offer Galapagos Biotech’s Jyseleca (filgotinib) to patients with moderate rheumatoid arthritis (RA), following a recommendation from the Scottish Medicines Consortium (SMC). ... We are delighted that people living with
Jyseleca (filgotinib) is an oral JAK inhibitor that can be administered as a monotherapy or used alongside another another common RA medicine called methotrexate. ... The FDA has expressed concerns regarding the overall benefit/risk profile of the
Following the disappointing results, Galapagos has lost out on the funds, with more pressure piled onto the other focal drug of the Gilead alliance – filgotinib. ... However, earlier this year the US Food and Drug Administration rejected Gilead’s
Biotech company Galapagos also announced last week that is has also postponed multiple studies of its experimental, Gilead-partnered drug filgotinib, which is currently in a range of late-stage studies
AbbVie’s Rinvoq (upadacitinib), Gilead/Galapagos’ filgotinib and Pfizer’s abrocitinib.
More from news
Approximately 3 fully matching, plus 28 partially matching documents found.
Recently, Galapagos and Gilead Sciences received a positive NICE recommendation for Jyseleca (filgotinib) for use on the NHS which, for the first time, will support access to an advanced therapy for
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... If approved, filgotinib will be a late entrant into a very
filgotinib for rheumatoid arthritis. ... and filgotinib’s anticipated launch this year meets expectations in the increasingly competitive market for JAK inhibitors.
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis. ... This will include broader commercial rights in Europe for filgotinib, due to be filed later this year, setting up a 2020 launch.
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest ... Likewise, upadacitinib will face competition
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...